Drug Profile
CB 4211
Alternative Names: CB-4211Latest Information Update: 30 Nov 2023
Price :
$50
*
At a glance
- Originator Albert Einstein College of Medicine; University of Southern California
- Developer CohBar
- Class Hepatoprotectants; Obesity therapies; Peptides; Small molecules
- Mechanism of Action Insulin receptor modulators; Lipolysis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis; Obesity
Most Recent Events
- 30 Nov 2023 CB 4211 is still in phase I trial for Non-alcoholic steatohepatitis in USA (SC, Injection) (CohBar pipeline, November 2023)
- 30 Nov 2023 CB 4211 is still in phase I trial for Obesity in USA (SC, Injection) (CohBar pipeline, November 2023)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis in USA (SC, Injection)